A5053706652- Intraperitoneal and Appendiceal Malignancies
- Hormonal Regulation and Hypertension
- Appendicitis Diagnosis and Management
- Ovarian cancer diagnosis and treatment
- Adrenal and Paraganglionic Tumors
- Anesthesia and Pain Management
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Intestinal and Peritoneal Adhesions
- Pain Management and Opioid Use
- Nausea and vomiting management
- Occupational and environmental lung diseases
- Breast Cancer Treatment Studies
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Screening and Detection
- Hernia repair and management
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Cardiac, Anesthesia and Surgical Outcomes
- Head and Neck Surgical Oncology
- Oral and Maxillofacial Pathology
- Economic and Financial Impacts of Cancer
- Nanoparticle-Based Drug Delivery
Hospital de Sant Joan Despí Moisès Broggi
2020-2025
Inova Fairfax Hospital
2015-2020
Virginia Commonwealth University
2019
Inova Health System
2019
MedStar Washington Hospital Center
2007-2017
Memorial Sloan Kettering Cancer Center
2013
Georgetown University
2013
Dana-Farber Cancer Institute
2013
University of Pittsburgh Medical Center
2013
Indiana University – Purdue University Indianapolis
2013
Abstract Background A treatment option for patients with peritoneal mucinous carcinomatosis (PMCA) from an appendiceal neoplasm is cytoreductive surgery and perioperative intraperitoneal chemotherapy. Also, these are recommended systemic chemotherapy using oxaliplatin 5‐fluorouracil (FOLFOX) regimen. major question concerns the proper timing (neoadjuvant vs. adjuvant) of Methods In January 2005 a prospective study was initiated to routinely treat dissemination adenocarcinoma appendix...
Background and Objectives. Systemic chemotherapy administered prior to cytoreductive surgery hyperthermic intraperitoneal (HIPEC) for peritoneal mucinous adenocarcinoma of appendiceal origin (PMCA) is associated with a significant rate histological response. The impact preoperative systemic (PSC) on tumor burden, completeness cytoreduction, perioperative complications unknown. Methods. We analyzed prospectively collected data from our HIPEC database. Thirty-four patients PMCA were recruited...
Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains mainstay treatment but disease recurrence death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients.
Background: PA is frequent in CRC patients and known to be detrimental surgical outcomes. PBM systems promote rational use of blood products treatment with IVI, which could potentially improve postoperative results the need for RBCT. Objective: To evaluate effectiveness Intravenous Iron (IVI) within a Patient Blood Management (PBM) pathway Colorectal Cancer (CRC) Preoperative Anemia (PA). analyze after Red Cell Transfusion (RBCT) surgery. Methods: Cohort study between 2012 2018, divided into...
Abstract Background Peritonectomy combined with perioperative intraperitoneal chemotherapy is a successful treatment option for patients peritoneal dissemination of appendiceal and colorectal malignancy. Despite its efficacy, recurrences remain common problem. Methods Patients from or malignancy who underwent complete cytoreduction were included in this study. Data regarding recurrent disease found on abdominal exploration and/or diagnostic studies was extracted prospective database...
Currently, the surgical management of pancreas cancer is recognized around world as inadequate. Despite a potentially curative R0 resection, long-term survival rare. There strong rationale for use chemotherapy in operating room to reduce local-regional recurrent/progressive disease. Gemcitabine monotherapy administered by an intraperitoneal route with hyperthermia and then treatment postoperatively has pharmacologic basis that exposure peritoneal surfaces gemcitabine approximately 200–500...
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal metastases. The optimal agents HIPEC have not been established. Melphalan drug broad activity and favorable profile application. purpose of this study to review our experience using melphalan HIPEC. Pharmacologic data was obtained. Thirty four patients who underwent CRS metastases received between 2003 2011. first 10 70 mg/m 2 ; subsequent 24 60 or . mean PCI was<mml:math...
Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has emerged as optimal treatment for diffuse malignant peritoneal mesothelioma (DMPM) showing median survivals of 36-92 months. However, recurrences occur frequently even in patients undergoing cytreduction and are often confined to the abdomen. We initiated a Phase II study adjuvant pemetrexed combined intravenous cisplatin CRS HIPEC DMPM. The consisted 500 mg/m(2) intraperitoneally 50 intravenously...
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been established as treatment options for patients with peritoneal metastases or mesothelioma. However, this novel strategy remains associated a large percentage of local-regional failures. These failures are attributed to the inadequacy HIPEC maintain surgical complete response. Management strategies supplement CRS indicated. A simplified approach intraoperative placement an port adjuvant bidirectional...
Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is a treatment option for patients with peritoneal metastases shown to provide improved overall survival appropriately selected patients. However, the availability utilization of this remains limited. The aim survey-based study was evaluate factors influencing physician choices metastases.Surveys were mailed medical oncologists surgeons in Virginia, Maryland, Washington, D.C. Survey questions evaluated access HIPEC...
<p>BRAF inhibitor suppresses subcutaneous tumor growth in a <i>BRAF</i><sup>V600E</sup> PMP-PDX model. mutant cells from PMP5.1 were subcutaneously implanted mice and treated with vehicle, intraperitoneal cetuximab (20 mg/kg), oral encorafenib or doublet (<i>n</i> = 10–12/group). <b>A,</b> Tumor curve of the overtime. Mean ± SEM is shown. <b>B,</b> Graphs show Western blot quantification pEGFR/EGFR (left) pERK/ERK (right)...
Background A successful new treatment for a particular disease may change the natural history of that as patients go on to longer survival. The goal this study was investigate porta hepatis site recurrence appendiceal mucinous neoplasms. Methods prospective database with peritoneal dissemination neoplasms has been maintained 21 years. In complete cytoreduction, progression/recurrence in and around noted manifestation disease. Results 710 treated cancer 140 developed recurrent Seven (5%) had...